8-K
filed December 19, 2025, 6:59 PM ET
ticker MGRX
CIK 0001938046
other material
confidence high
sentiment neutral
materiality 0.70
Mangoceuticals raises $2.5M via registered direct offering and private placement
MANGOCEUTICALS, INC.
- $2.5M gross proceeds from sale of 1.43M common shares at $1.295 and 500K pre-funded warrants at $1.29499.
- Private placement includes warrants for up to 1.93M shares at $1.4245; exercisable for 5 years.
- Net proceeds for working capital and general corporate purposes; closing expected Dec 19, 2025.
- Aegis Capital Corp acts as placement agent; offering under effective shelf registration S-3.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
MANGOCEUTICALS, INC. issued an aggregate of up to 1,930,502 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds of approximately $2.5 million.
- Security
- warrant
- Shares
- an aggregate of up to 1,930,502 shares of Common Stock
- Purchaser
- institutional investor
- Consideration
- aggregate gross proceeds of approximately $2.5 million
Exact text from the filing
exercisable for an aggregate of up to 1,930,502 shares of Common Stock, at an exercise price of $1.4245 per warrant share for aggregate gross proceeds of approximately $2.5 million. The Pre-Funded Warrants are immediately exercisable and may be exercised at an exercise price of $0.00001 per warrant share at any time until all of the Pre-Funded Warrants are
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
MANGOCEUTICALS, INC. issued 1,430,502 shares of common stock to institutional investor for $1.295 per share.
- Security
- common stock
- Shares
- 1,430,502 shares
- Purchaser
- institutional investor
- Consideration
- $1.295 per share
Exact text from the filing
registered direct offering, (A) 1,430,502 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $1.295 per share, and (B) 500,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of the Common Shares, at an offering price of $1.29499 per Pre-Funded Warrant (such registered
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
MANGOCEUTICALS, INC. issued 500,000 pre-funded warrants of warrant to institutional investor for $1.29499 per Pre-Funded Warrant.
- Security
- warrant
- Shares
- 500,000 pre-funded warrants
- Purchaser
- institutional investor
- Consideration
- $1.29499 per Pre-Funded Warrant
Exact text from the filing
registered direct offering, (A) 1,430,502 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $1.295 per share, and (B) 500,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of the Common Shares, at an offering price of $1.29499 per Pre-Funded Warrant (such registered
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
MANGOCEUTICALS, INC. entered into Purchase Agreement with an institutional investor valued at aggregate gross proceeds of approximately $2.5 million (effective 2025-12-18).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an institutional investor
- Value
- aggregate gross proceeds of approximately $2.5 million
- Effective
- 2025-12-18
Exact text from the filing
On December 18, 2025, Mangoceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to such investor (a) in a registered direct offering, (A) 1,430,502 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $1.295 per share, and (B) 500,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of the Common Shares, at an offering price of $1.29499 per Pre-Funded Warrant (such registered direct offering, the “Offering”), and (b) in a concurrent private placement, common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 1,930,502 shares of Common Stock, at an exercise price of $1.4245 per warrant share for aggregate gross proceeds of approximately $2.5 million.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.